Genetic Analysis’ CTO finalist in the Lyfebulb and Bristol Myers Squibb Innovation Challenge addressing unmet needs in IBD
OSLO, NORWAY, January 27, 2023 – Molecular diagnostics specialist, Genetic Analysis AS (“GA”) is happy to announce that GA’s Chief Technology Officer Kari Furu was a finalist in the Lyfebulb…
Genetic Analysis AS achieves Thai FDA License for GA-map® Dysbiosis Test in Thailand
OSLO, NORWAY – 19 January 2023: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) are happy to announce that Thailand Food and Drug Administration (“Thai FDA”) authority have granted GA license…
Genetic Analysis AS enters an agreement with Microbiome Research Pvt. Ltd. to launch GA-map® technology in India
OSLO, NORWAY – 16 January 2023: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) has entered a Tech Transfer Agreement with Microbiome Research Pvt. Ltd. (“MRPL”), a Mumbai based biotechnology company…
Genetic Analysis AS enters an agreement with Hausen Bernstein Co. Ltd. to launch GA-map® technology in Thailand
OSLO, NORWAY – November 30, 2022: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) has entered a tech transfer and distribution agreement with Hausen Bernstein Co. Ltd. (“HB”), a Bangkok-based fast-growing…
Genetic Analysis AS announces the outcome of the warrant exercise
Oslo, Norway, November 21, 2022 – On November 16, 2022, the exercise period for Genetic Analysis AS’s (“GA” or the “Company”) warrants of series TO 1, issued in connection with…
Genetic Analysis AS enters an agreement with a major diagnostic company for distribution of GA-map® in Europe
OSLO, NORWAY – 7 November 2022: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) today announces that GA has entered into an agreement with a leading non-disclosed global diagnostic company for…
Information regarding the exercise period of warrants of series TO 1 in Genetic Analysis
Oslo, Norway, November 2, 2022 – On November 2, 2022, the exercise period for the warrants of series TO 1 issued in connection with Genetic Analysis AS’s (“GA” or the…
Interim report January – September 2022
Oslo, Norway, November 1, 2022 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the period January 1 – September 30, 2022. The interim report…
Genetic Analysis appoints Sedermera Corporate Finance AB to act as a liquidity provider for the Company´s share
Oslo, Norway, September 1, 2022 – Genetic Analysis AS (“GA” or “the Company”) has appointed Sedermera Corporate Finance as the Company’s liquidity provider. The assignment will commence on the 5…
Interim report January – June 2022
Oslo, Norway, August 18, 2022 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the period January 1 – June 30, 2022. The interim report…
Genetic Analysis and Servatus enter Strategic Collaboration Agreement to develop new microbiome diagnostic and therapeutic solutions
The Strategic Collaboration Agreement will enable both parties to utilise extensive knowledge sharing for microbiome diagnostics and biotherapeutics development Genetic Analysis is a Norway-based diagnostic company and a pioneer in…
Genetic Analysis AS: Mandatory notification of trade – Primary Insider
OSLO, NORWAY – 20 May 2022: Genetic Analysis AS (“GA” or “the Company”) announce that a member of the management has bought GEAN-shares. Ronny Hermansen, CEO in Genetic Analysis AS,…
Genetic Analysis AS and Omnigene Medical Technologies Ltd. enter a distribution agreement to launch GA-map® in the United Arabic Emirates (UAE) market
OSLO, NORWAY – May 19, 2022: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) hereby announces that GA has entered a distribution and technology transfer agreement with Omnigene Medical Technologies Ltd….
Interim report January – March 2022
Oslo, Norway, May 13, 2022 – Genetic Analysis AS (“GA” or “the Company”) hereby publishes the interim report for the period January 1 – March 31, 2022. The interim report…
Minutes from the Annual General Meeting 2022 in Genetic Analysis AS
Oslo, Norway, April 29, 2022 – Genetic Analysis AS (the “Company”, Ticker: GEAN) held its Annual General Meeting on April 28 at 15:00 hours (CET) on the Company’s premises in…